About DPB Group
DPB Group is a company based in Mumbai (India) founded in 2005 by Bill Sanders and Mark Williams. It operates as a B2B2C and Reseller / Distribution. DPB Group offers products and services including Active Pharmaceutical Ingredients (APIs), Contract Manufacturing, Integrated Supply Chain, Pharmaceutical Indenting, and Regulatory Consulting. DPB Group operates in a competitive market with competitors including WuXi AppTec, Eurofins Scientific, Ipsen, ANI Pharmaceuticals and Red Nucleus, among others.
- Headquarter Mumbai, India
- Founders Bill Sanders, Mark Williams
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dpb Pharmaceuticals Ltd.
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$22.8 M (USD)0as on Mar 31, 2023
-
Net Profit
$1.45 M (USD)0as on Mar 31, 2023
-
EBITDA
$2.02 M (USD)0as on Mar 31, 2023
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DPB Group
DPB Group offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Contract Manufacturing, Integrated Supply Chain, Pharmaceutical Indenting, and Regulatory Consulting.
APIs are manufactured for pharmaceutical industry applications.
Manufacturing services are provided for pharmaceutical products.
Supply chain solutions are offered for pharmaceutical distribution.
Indenting services are facilitated for pharmaceutical procurement needs.
Consulting services are provided for pharmaceutical regulatory compliance.
Funding Insights of DPB Group
Detailed funding history for DPB Group
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DPB Group
Investment portfolio details for DPB Group
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DPB Group
Detailed financials for DPB Group
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dpb Group Comparisons
Peer comparison for DPB Group
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DPB Group
DPB Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as WuXi AppTec, Eurofins Scientific, Ipsen, ANI Pharmaceuticals and Red Nucleus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of CRO and CDMO services
|
|
| Locked | Locked | Locked |
Laboratory testing and contract research services are provided globally.
|
|
| Locked | Locked | Locked |
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes
|
|
| Locked | Locked | Locked |
Branded and generic prescription drugs are developed, manufactured, and marketed.
|
|
| Locked | Locked | Locked |
Advisory, scientific, and medical communications provided for pharmaceutical industry.
|
|
| Locked | Locked | Locked |
Regulatory support, brand differentiation, and prototyping services are provided.
|
Detailed competitors of DPB Group
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dpb Group
Complete news archive for DPB Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DPB Group
DPB Group was founded in 2005.
DPB Group is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Annual revenue of DPB Group is $22.8M as on Mar 31, 2023.
DPB Group is involved in the production of sterile and oral antibiotic APIs, serving the pharmaceutical industry in India and globally. The company is based in Mumbai and operates with a focus on quality and innovation. Solutions are provided across diverse markets through an expansive distribution network. Plans are underway to establish a pioneering unit for potassium clavulanate in India, positioning the company as a significant player in the global pharmaceutical sector. Services such as contract manufacturing, integrated supply chain management, and regulatory consulting are also offered to support industry needs.
DPB Group's top competitors include WuXi AppTec, ANI Pharmaceuticals and Aptar.
DPB Group offers Active Pharmaceutical Ingredients (APIs), Contract Manufacturing, Integrated Supply Chain, Pharmaceutical Indenting, and Regulatory Consulting.